Clinical TrialAug 3, 2026, 08:07 AM
Candel Therapeutics Abstract Accepted for ASTRO 2026 Presentation
AI Summary
Candel Therapeutics, Inc. announced that an abstract detailing its aglatimagene besadenovec immunotherapy for localized prostate cancer has been accepted for a poster presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The presentation will take place on September 29, 2026. This highlights the company's progress in developing multimodal immunotherapies for cancer, with aglatimagene besadenovec already holding FDA Fast Track and RMAT designations.
Key Highlights
- Candel Therapeutics' abstract accepted for poster presentation at ASTRO 2026 Annual Meeting.
- Presentation focuses on aglatimagene besadenovec for localized prostate cancer.
- The poster will be presented on September 29, 2026, in Boston, MA.
- Aglatimagene besadenovec is the lead product from Candel's adenovirus platform.
- Aglatimagene besadenovec has FDA Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations for localized prostate cancer.
- Candel also has linoserpaturev (HSV platform) in Phase 1b for recurrent high-grade glioma.
Price Impact
More from CADL